CSPC Pharmaceutical Group (FRA:CVGU) Beneish M-Score: -2.63 (As of Jun. 25, 2026)


FRA:CVGU CSPC Pharmaceutical Group Ltd FRA:CVGU
88 GF Score
Price €2.74
GF Value €2.72
! 4 Warning Signs
View Full Analysis

What is CSPC Pharmaceutical Group Beneish M-Score?

CSPC Pharmaceutical Group FRA:CVGU +0.74% 88 Beneish M-Score is -2.63 as of Jun. 25, 2026. GuruFocus rates FRA:CVGU with a GF Score™ of 88/100 and a GF Value™ of €2.72. The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, CSPC Pharmaceutical Group ranks better than 62.02% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.63 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for CSPC Pharmaceutical Group's Beneish M-Score or its related term are showing as below:

FRA:CVGU' s Beneish M-Score Range Over the Past 10 Years
Min: -2.71   Med: -2.35   Max: -1.94
Current: -2.63

During the past 13 years, the highest Beneish M-Score of CSPC Pharmaceutical Group was -1.94. The lowest was -2.71. And the median was -2.35.


CSPC Pharmaceutical Group Beneish M-Score Historical Data

* Premium members only.

The historical data trend for CSPC Pharmaceutical Group's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSPC Pharmaceutical Group Beneish M-Score Chart

CSPC Pharmaceutical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.10 -2.59 -1.95 -2.40 -2.63

CSPC Pharmaceutical Group Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.63 0.00

FRA:CVGU vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSPC Pharmaceutical Group Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CSPC Pharmaceutical Group's Beneish M-Score falls into.


FRA:CVGU
88GF Score
CSPC Pharmaceutical Group Ltd FRA:CVGU
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSPC Pharmaceutical Group Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CSPC Pharmaceutical Group for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0312+0.528 * 1.0668+0.404 * 1.0494+0.892 * 0.8287+0.115 * 1.0165
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8346+4.679 * -0.041748-0.327 * 1.0161
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €1,114 Mil.
Revenue was €3,153 Mil.
Gross Profit was €2,068 Mil.
Total Current Assets was €2,698 Mil.
Total Assets was €5,662 Mil.
Property, Plant and Equipment(Net PPE) was €1,703 Mil.
Depreciation, Depletion and Amortization(DDA) was €171 Mil.
Selling, General, & Admin. Expense(SGA) was €884 Mil.
Total Current Liabilities was €1,234 Mil.
Long-Term Debt & Capital Lease Obligation was €22 Mil.
Net Income was €471 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €707 Mil.
Total Receivables was €1,304 Mil.
Revenue was €3,805 Mil.
Gross Profit was €2,663 Mil.
Total Current Assets was €2,871 Mil.
Total Assets was €5,822 Mil.
Property, Plant and Equipment(Net PPE) was €1,716 Mil.
Depreciation, Depletion and Amortization(DDA) was €176 Mil.
Selling, General, & Admin. Expense(SGA) was €1,278 Mil.
Total Current Liabilities was €1,264 Mil.
Long-Term Debt & Capital Lease Obligation was €7 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1113.95 / 3153.269) / (1303.606 / 3805.106)
=0.353268 / 0.342594
=1.0312

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2662.556 / 3805.106) / (2068.373 / 3153.269)
=0.699732 / 0.655946
=1.0668

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2697.925 + 1703.09) / 5662.202) / (1 - (2871.04 + 1715.556) / 5822.447)
=0.222738 / 0.212256
=1.0494

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3153.269 / 3805.106
=0.8287

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(175.694 / (175.694 + 1715.556)) / (171.298 / (171.298 + 1703.09))
=0.092898 / 0.091389
=1.0165

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(883.771 / 3153.269) / (1277.834 / 3805.106)
=0.280271 / 0.335821
=0.8346

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((21.909 + 1234.084) / 5662.202) / ((7.363 + 1263.683) / 5822.447)
=0.221821 / 0.218301
=1.0161

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(470.712 - 0 - 707.096) / 5662.202
=-0.041748

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CSPC Pharmaceutical Group has a M-score of -2.72 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.63 mean?
CSPC Pharmaceutical Group (FRA:CVGU) has a Beneish M-Score of -2.63 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on CSPC Pharmaceutical Group and its competitors. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #346 out of 911 companies in the Drug Manufacturers industry, placing it in the top 38%.
Is CSPC Pharmaceutical Group's Beneish M-Score too high?
CSPC Pharmaceutical Group's current Beneish M-Score is -2.63. Based on the distribution chart, CSPC Pharmaceutical Group ranks #346 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CSPC Pharmaceutical Group has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #346 out of 911 companies for Beneish M-Score. This puts CSPC Pharmaceutical Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on CSPC Pharmaceutical Group and its competitors. CSPC Pharmaceutical Group's current Beneish M-Score is -2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
CSPC Pharmaceutical Group (FRA:CVGU) has a current Beneish M-Score of -2.63. The stock's GF Value™ is €2.72, compared to a current price of €2.74 — trading 0.7% above its estimated fair value. The current Beneish M-Score is -2.63. CSPC Pharmaceutical Group's overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For CSPC Pharmaceutical Group (FRA:CVGU), the current Beneish M-Score is -2.63 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSPC Pharmaceutical Group (FRA:CVGU) Overvalued in 2026?

Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued. The current stock price of €2.74 is trading 0.7% above its estimated GF Value™ of €2.72.

Key valuation signals for FRA:CVGU:

  • Beneish M-Score: -2.63
  • GF Value™: €2.72 vs. price of €2.74 (0.7% above fair value)
  • GF Score™: 88/100 with 4 warning signs

No single metric tells the full story. See the FRA:CVGU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSPC Pharmaceutical Group Business Description

Address No.896 Zhongshandong Street, Gaoxin District, Hebei Province, Shijiazhuang, CHN, 050035
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
88GF Score

Get the complete analysis for FRA:CVGU

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price
€2.72
GF Value